Natco Pharma Q3 FY26 Earnings Call Transcript Released
Natco Pharma released its Q3 FY26 earnings call transcript. The company reported Q3 FY26 revenue of ₹705.4 crore and net profit of ₹151.3 crore. An interim dividend of ₹1.5 per share was declared. The company is pursuing acquisitions and expects FY26 revenue of ₹4,200-4,300 crore. Semaglutide launch is anticipated to drive domestic growth.
The transcript provides detailed financial results, strategic outlook, and updates on key product pipelines and future acquisitions. This information is material for investors and analysts in understanding the company's performance and future prospects.
The announcement is a transcript of an earnings call, which is primarily informational. While financial results were shared, the call also included discussions on ongoing litigation, future acquisitions, and market strategies, making the overall sentiment neutral.
Natco Pharma Limited has released the transcript of its earnings conference call for the third quarter of FY25-26, which was held on February 12, 2026. The transcript is available on the company's website. During the call, the company reported consolidated total revenue of ₹705.4 crore for the quarter ended December 31, 2025, an increase from ₹651.1 crore in the same period last year. EBITDA stood at ₹216.8 crore with a margin of 30.7%, and net profit was ₹151.3 crore.
The company also provided updates on its associated company, Adcock Ingram Holdings, where its share of profit for the period November 10 to December 31, 2025, after amortization, was ₹10.9 crore. The Board of Directors declared an interim dividend of ₹1.5 per equity share.
Discussions during the call included the expected approval for GLP-1 in February 2026, with the company currently outsourcing fill and finish capacity. Natco Pharma is focusing on regulated markets for emerging markets. Regarding potential share buybacks, the management indicated a preference to preserve cash for future acquisitions, similar in size to the Adcock acquisition. The company is actively pursuing two to three acquisition targets, aiming to close at least one large transaction in 2026.
Further details were provided on the domestic semaglutide launch for both diabetes and weight loss indications, with approvals expected soon. The company is also litigating patent cases related to this molecule. Export formulations saw a year-on-year uptick of approximately ₹135 crore, driven by strong performance in subsidiaries in Brazil and Canada, and the Middle East, rather than Revlimid. The Crop Health Sciences demerger is targeted for October-November 2026.
Natco Pharma is exploring new acquisition opportunities, particularly in emerging markets and established brand businesses, with a focus on opportunities outside India due to higher potential returns. The company anticipates revenue of ₹4,200-4,300 crore for FY26 and PAT of around ₹1,280-1,300 crore. Semaglutide is expected to be a significant driver for India's domestic revenue growth, aiming for over 20% growth. The company also discussed its NCE pipeline, highlighting eGenesis as a promising investment in CRISPR-Cas9 technology with disruptive potential.
What to do with a filing like this
Natco Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Natco Pharma Limited. Read the original for the full detail.